Medical News

RSS

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).

7 Jun 2011

Researchers reveal surprising link between cell's skeleton and organ size

A group of scientists at the Instituto Gulbenkian de Ci-ncia, in Portugal, have uncovered a surprising link between the cell's skeleton and organ size. The team, led by Florence Janody, show in the journal Development, that one of the proteins that regulates the skeleton of the cell also acts to blocks activation of genes that promote cell survival and proliferation.

7 Jun 2011

David Cameron’s NHS promises

Prime Minister David Cameron gives out “five guarantees” regarding the future of the NHS in England amid details of when changes to planned reforms will be considered. He promised that NHS will remain free at the point of use, care will be improved and budgets will rise and waiting times will be “kept low”.

7 Jun 2011

Homelessness and mental illness link explored in RMIT study

In a new study by the RMIT University, Victoria researchers looked at cases of 4,291 people using homelessness services in the city. Dr Guy Johnson and Professor Chris Chamberlain found almost half of them - 46 per cent - lost their homes after a family breakdown. This is contrary to the long held belief that most homeless people are mentally unstable.

7 Jun 2011

Thermo Fisher Scientific unveils three new mass spectrometry products at 59th Annual ASMS Conference

Thermo Fisher Scientific Inc., the world leader in serving science, introduced three breakthrough instruments that take mass spectrometry (MS) analysis to new levels of performance in resolution, speed, sensitivity and accuracy. The new instruments were unveiled at the 59th Annual ASMS Conference on Mass Spectrometry and Allied Topics, being held June 5-9 at the Colorado Convention Center.

From Thermo Fisher Scientific Inc. 7 Jun 2011

Jindal's Medicaid plan questioned; Wash. lawmakers enact fee on nursing homes to increase federal match

Calling it a "dubious privatization venture," a Baton Rouge good-government group last week questioned Gov. Bobby Jindal's plan to turn over large chunks of the state Medicaid program to private insurers and praised the Louisiana House of Representatives for trying to slow the process.

7 Jun 2011

HIV positive man puts three women at risk

An HIV-positive man, John Choul Chan, 42, of Findon, South Australia, admitted to endangering the lives of three women through unprotected sex.

7 Jun 2011

Manhattan acquires Senior Scientific

In a move to accelerate applications of a novel cancer detection and treatment technology, Manhattan Scientifics today announced that it has acquired all of Senior Scientific, LLC and its affiliate Scientific Nanomedicine Inc.

7 Jun 2011

Gay, bisexual teenagers more likely to engage in risky behavior

A new report finds that gay, lesbian and bisexual high school students are more likely than heterosexual students to engage in such risky behavior as smoking, drinking alcohol and carrying guns. The study by the Centers for Disease Control and Prevention (CDC) surveyed 156,000 high school students and was released on Monday. This is the largest of its kind by the federal government.

7 Jun 2011

Flaxseed of no use in menopausal hot flashes: Study

Flaxseed has been the latest agent that has been tried in treating menopausal hot flashes and it is seen that it does not reduce the incidence of the unpleasant symptoms.

7 Jun 2011

Actavis receives final FDA approval for Zolpidem ER Tablets

Actavis, an international generic pharmaceuticals company, today announced that it has received final approval from the US Food & Drug Administration to market Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV. Distribution of the product has commenced.

7 Jun 2011

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2011

Tikcro reports net loss of $30,000 for first quarter 2011

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2011.

7 Jun 2011

ITI receives FDA clearance for new Q fever assay kit

This week the U.S. Food and Drug Administration cleared the first nucleic acid amplification In vitro diagnostic (IVD) test that detects Coxiella burnetii, the bacteria that causes Q fever.

7 Jun 2011

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Celator Pharmaceuticals today announced positive clinical results in elderly patients with newly-diagnosed secondary acute myeloid leukemia (sAML) treated with CPX-351 Liposome Injection.

7 Jun 2011

3M introduces Kind Removal Silicone Tape for patients with sensitive, at-risk skin

3M Skin and Wound Care introduces 3M Kind Removal Silicone Tape with a new, silicone-based, adhesive technology that provides an optimal balance of securement and gentleness.

7 Jun 2011

Frog skin proteins could treat cancer, diabetes and stroke: New discovery

Scientists at Queen's University Belfast have discovered proteins in frog skins which could be used to treat cancer, diabetes, stroke and transplant patients by regulating the growth of blood vessels.

7 Jun 2011

DiagnoCure reports net loss of $1,601,439 for second quarter 2011

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported financial and operation results for the second quarter of fiscal 2011.

7 Jun 2011

Focus on getting more people on antiretroviral therapy as AIDS turns 30

Sunday marked the 30th anniversary of the first published report of the disease that came to be known as AIDS, the Los Angeles Times reports. Though the "promise" of a vaccine "has not materialized," "[s]ome progress has been made on other fronts," the newspaper writes.

7 Jun 2011

Regenesis Biomedical closes $5.3M Series C equity financing

Regenesis Biomedical, Inc., a medical technology company that markets the Provant Therapy System, announced today the closing of a $5.3 million Series C equity financing.

7 Jun 2011